Zevra Therapeutics Inc (ZVRA)
9.585
+0.46
(+4.98%)
USD |
NASDAQ |
Nov 22, 16:00
9.64
+0.06
(+0.57%)
After-Hours: 20:00
Zevra Therapeutics Revenue (TTM): 24.49M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 24.49M |
| June 30, 2024 | 23.69M |
| March 31, 2024 | 27.71M |
| December 31, 2023 | 27.46M |
| September 30, 2023 | 16.56M |
| June 30, 2023 | 16.54M |
| March 31, 2023 | 9.372M |
| December 31, 2022 | 10.16M |
| September 30, 2022 | 10.72M |
| Date | Value |
|---|---|
| June 30, 2022 | 9.812M |
| March 31, 2022 | 20.50M |
| December 31, 2021 | 28.65M |
| September 30, 2021 | 28.43M |
| June 30, 2021 | 28.39M |
| March 31, 2021 | 23.32M |
| December 31, 2020 | 13.29M |
| September 30, 2020 | 12.30M |
| June 30, 2020 | 21.84M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
9.372M
Minimum
Mar 2023
28.65M
Maximum
Dec 2021
19.62M
Average
21.17M
Median
Revenue (TTM) Benchmarks
| Johnson & Johnson | 87.70B |
| Ionis Pharmaceuticals Inc | 803.07M |
| Vanda Pharmaceuticals Inc | 190.86M |
| BioCardia Inc | -- |
| Xeris Biopharma Holdings Inc | 187.36M |